Andere talen Relmada Therapeutics, Inc.

Aandelen

RLMD

US75955J4022

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 25-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
3,7 ^USD	-4,15%		-13,95%	-10,63%

19/03	Transcript : Relmada Therapeutics, Inc., 2023 Earnings Call, Mar 19, 2024
19/03	Relmada Therapeutics, Inc. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results	20/03
Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024	12/03
Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference	05/03
Relmada Says Chief Medical Officer Leaving; Names Senior Clinical Development Advisor	04/01
Relmada Therapeutics Provides Corporate Update	04/01
Relmada Therapeutics, Inc. Announces Resignation of Cedric O?Gorman as Chief Medical Officer	03/01
Relmada Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11
Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023	03/11
Relmada Therapeutics Reports Positive Preclinical Data on its Psilocybin Program to Treat Liver Disease	11-10-23
Relmada Therapeutics to Present New Preclinical Data on Its Psilocybin Program At AASLD the Liver Meeting 2023	11-10-23
Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS, Neuro Summit	10-10-23
Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology Congress	09-10-23
Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit	09-10-23
Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress	06-10-23
Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder	20-09-23
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from S&P Global BMI Index	18-09-23
Relmada Therapeutics, Inc. Announces Eric Schmidt to Resign from the Board, Chairman of the Audit Committee of the Board and as A Member of the Corporate Governance and Nominating Committee of the Board	06-09-23
Relmada Therapeutics Doses First Person in Phase 3 Trial of REL-1017 for Major Depressive Disorder	23-08-23
Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder	23-08-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Relmada Therapeutics, Inc.

Aandelen

RLMD

US75955J4022

Andere talen

Filters